Abstract
Background and objective SARS-CoV-2 infection poses tremendous challenge to the healthcare system of nations across the globe. Serological testing for SARS-CoV-2 infection in healthcare workers, which form a high-risk group, helps in identifying the burden of hidden infection in an institutional setting.
Methods We present the results of a cross-sectional serosurvey in healthcare workers from two different hospital settings based on their role in the management of SARS-CoV-2 patients in District Srinagar, Kashmir. In addition to testing for the presence of SARS-CoV-2 specific IgG, we collected information on influenza-like symptoms in the last four weeks and the status of RT-PCR testing. SARS-CoV-2 specific IgG antibodies were detected in serum samples using a sensitive and specific chemiluminescent microparticle immunoassay technology.
Interpretation and Conclusion Of 2915 healthcare workers who participated in the study, we analysed data from 2905 healthcare workers. The overall prevalence of SARS-CoV-2 specific IgG antibodies was 2.5% (95% CI 2.0-3.1) in the healthcare workers of District Srinagar. Healthcare workers who had ever worked at a dedicated-COVID hospital had a substantially lower seroprevalence of 0.6% (95% CI: 0.2 - 1.9). Among healthcare workers who had tested positive for RT-PCR, seroprevalence was 27.6% (95% CI: 14.0 - 47.2).The seroprevalence of SARS-CoV-2 infection in healthcare workers of District Srinagar is low, reflecting that a high proportion of healthcare workers are still susceptible to the infection. It is crucial to lay thrust on infection prevention and control activities and standard hygiene practices by the healthcare staff to protect them from acquiring infection within the healthcare setting.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study received mainly institutional funding from Government Medical College Srinagar with support from District Disaster Management Authority Srinagar. The funding bodies have no role in design, collection, analysis, interpretation, or writing of manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IT IS AN OBSERVATIONAL STUDY INTSTITUTIONAL ETHICAL COMMITTEE GMC SRINAGAR
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email id:smsalimkhan2{at}gmail.com
Email id:haqinaam{at}yahoo.co.in
Email id:maryaamin123{at}gmail.com
Email id:zululubaba{at}gmail.com
Email id:ariefbhat19{at}gmail.com
Email id:obaid527{at}gmail.com
Email.id:qazitanzee{at}gmail.com
Email.id:iqranisar92{at}gmail.com
Email.id:iramsabah{at}yahoo.com
Email.id:misbah.dps{at}gmail.com
Email.id:loneaziz7{at}gmail.com
Email.id:dr.shahroznabi{at}gmail.com
Email.id:dr.isumji{at}gmail.com
Email.id:rafia219{at}gmail.com
Data Availability
THE DATA WILL BE MADE AVAILABLE ON REQUEST
List of abbreviations
- SARS-CoV-2
- Severe acute respiratory syndrome coronavirus 2
- COVID-19
- Coronavirus disease
- CMIA
- Chemiluminescent microparticle immunoassay
- CI
- Confidence interval
